Cargando…

Tocilizumab for the treatment of refractory pediatric mixed connective tissue disease (MCTD), in two patients

Detalles Bibliográficos
Autores principales:	Cabrera, Natalia, Chastang, Marie Caroline, Desjonquères, Marine, Duquesne, Agnes, Cochat, Pierre, Belot, Alexandre
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4191593/ http://dx.doi.org/10.1186/1546-0096-12-S1-P303

Ejemplares similares

Tocilizumab in the treatment of mixed connective tissue disease and overlap syndrome in children
por: Cabrera, Natalia, et al.
Publicado: (2016)

Exercise limitation in juvenile onset Mixed Connective Tissue Disease (MCTD)
por: Net, JJ van der, et al.
Publicado: (2008)

TNFa, IL10 and TGFb1 gene polymorphism in myositis and mixed connective tissue disease (MCTD)
por: Hassan, A, et al.
Publicado: (2001)

Interferons (IFN-A/-B/-G) Genetic Variants in Patients with Mixed Connective Tissue Disease (MCTD)
por: Paradowska-Gorycka, Agnieszka, et al.
Publicado: (2019)

Capillaroscopy as a diagnostic tool in the diagnosis of mixed connective tissue disease (MCTD): a case report
por: Radić, Mislav, et al.
Publicado: (2021)

Facial Myokymia Due to a Pontine Inflammatory Demyelinating Disorder Associated with Mixed Connective Tissue Disorder [MCTD]
por: Maramattom, Boby Varkey
Publicado: (2020)

PReS-FINAL-2231: A series of 41 mutations of TNFRAF1A
por: Chastang, MC, et al.
Publicado: (2013)

12. First presentation of MCTD as severe pulmonary hypertension during pregnancy
por: Raghunath, Radhika, et al.
Publicado: (2017)

Relapsing polychondritis: a pediatric series of ten patients
por: Belot, A, et al.
Publicado: (2008)

PReS-FINAL-2284: SLE and complement deficiencies: a French multicentric retrospective study
por: Roland-Gosselin, B, et al.
Publicado: (2013)

The efficacy and safety of Tocilizumab in adults with refractory systemic onset JIA
por: Deslypere, G, et al.
Publicado: (2011)

Tocilizumab for refractory Castleman’s disease with paraneoplastic pemphigus and Behçet’s disease
por: Vargas, Ana Beatriz, et al.
Publicado: (2012)

Takayasu arteritis in children
por: Al abrawi, Safia, et al.
Publicado: (2008)

Metacognitive training for delusions (MCTd): effectiveness on data-gathering and belief flexibility in a Chinese sample
por: So, Suzanne Ho-Wai, et al.
Publicado: (2015)

The Serum Cell-Free microRNA Expression Profile in MCTD, SLE, SSc, and RA Patients
por: Stypinska, Barbara, et al.
Publicado: (2020)

PReS-FINAL-2311: Rituximab in paediatric ANCA-associated vasculitis
por: Mestrallet, G, et al.
Publicado: (2013)

Collaboration in long term follow-up of juvenile idiopathic arthritis
por: Larbre, JP, et al.
Publicado: (2008)

PReS-FINAL-2110: Tocilizumab for patients with oligoarticular juvenile idiopathic arthritis refractory to conventional therapy
por: Sato, T, et al.
Publicado: (2013)

Prescribed but not approved: biologic agents used without approval in juvenile idiopathic arthritis in Switzerland, France and Belgium
por: Woerner, Andreas, et al.
Publicado: (2014)

PW02-016 - 41 cases of TRAPS, a rare autoinflammatory disease
por: Chastang, M-C, et al.
Publicado: (2013)

Longitudinal immunomonitoring following Tocilizumab in rheumatoid arthritis
por: Pers, Yves-Marie, et al.
Publicado: (2011)

Pyrin dephosphorylation is sufficient to trigger inflammasome activation in familial Mediterranean fever patients
por: Magnotti, Flora, et al.
Publicado: (2019)

Intravenous tocilizumab in idiopathic pediatric uveitis with refractory cystoid macular edema – A case report
por: Babu, Kalpana, et al.
Publicado: (2019)

55. A case for continuing tocilizumab beyond 12 months in giant cell arteritis?
por: Ming, Caroline, et al.
Publicado: (2019)

Tocilizumab administration in a refractory case of COVID-19
por: Dastan, Farzaneh, et al.
Publicado: (2020)

Tocilizumab for refractory morphea in adults: A case series
por: Lonowski, Sarah, et al.
Publicado: (2022)

Subcutaneous Tocilizumab May Be Effective in Refractory Fibromyalgia Patients
por: Tang, Kuo-Tung, et al.
Publicado: (2023)

Treatment of MAS and HLH
por: Belot, Alexandre
Publicado: (2014)

Refractory Uveitis in Patient with Castleman Disease Successfully Treated with Tocilizumab
por: Oshitari, Toshiyuki, et al.
Publicado: (2012)

Tocilizumab for refractory severe immune checkpoint inhibitor-associated myocarditis
por: Doms, J., et al.
Publicado: (2020)

Resolution of cryptogenic new onset refractory status epilepticus with tocilizumab
por: Donnelly, Jonathan P., et al.
Publicado: (2021)

Randomized Trial of Tocilizumab in the Treatment of Refractory Adult Polymyositis and Dermatomyositis
por: Oddis, Chester V., et al.
Publicado: (2022)

Myositis as a rare complication after tocilizumab treatment
por: Quesada-Masachs, Estefania, et al.
Publicado: (2014)

20. Tocilizumab: is out of sight really out of mind?
por: Khalid, Salema, et al.
Publicado: (2019)

Sustained remission of Multicentric Castleman Disease in children treated with tocilizumab
por: Galeotti, C, et al.
Publicado: (2011)

Tocilizumab-effects on growth impairment in systemic juvenile idiopathic arthritis
por: Miyamae, Takako, et al.
Publicado: (2011)

Safety and efficacy of tocilizumab in children with systemic juvenile idiopathic arthritis
por: Horneff, G, et al.
Publicado: (2015)

H syndrome treated with Tocilizumab: two case reports and literature review
por: Jacquot, Robin, et al.
Publicado: (2023)

SAT-500 Response to Tocilizumab Retreatment in Refractory Thyroid Eye Disease
por: Kaplan, Daniel, et al.
Publicado: (2020)

High levels of TNFα in patients with COVID-19 refractory to tocilizumab
por: Danlos, F.X., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_oh3k6dthgcobsfb61if58ouuom